This discussion includes Dr. Williams’ work with gene therapy, cancer research, and follistatin — a myostatin inhibitor. he administered to himself years ago.

Dr. Williams, CMO of BioViva Science, is a radiologist with a passion for gene and cellular therapies that can be administered under image guidance. He also has an interest in image guided cancer therapies. He did research for several years with adenoviral vector technology for the treatment of cancer. He has spent the last five years involved in research using AAV technology. Dr. Williams obtained his medical degree from Louisiana State University and completed an internship in Internal Medicine followed by a residency in Radiology at The University Of South Alabama. In residency, he was selected for the RSNA Research Fellow award.

He is board certified by The American Board of Radiology with additional training in image guided cancer and spine procedures. His research interest is in gene therapy and re-programming of stem cells. He also has research interests in the use of CT and MRI guidance for minimally invasive procedures related to the spine and treatment of cancer.

Wlliams Cancer Institute:
https://williamscancerinstitute.com/

Charlie Ilsley, the 13 year old being treated by Dr. Williams:
https://www.henleystandard.co.uk/news/home/152534/family-to-…tment.html

Learn more about follistatin gene therapy :

Dr. Anthony Fauci: “When you’re dealing with something that’s changing in real time—that’s really the nature of science.”

“As the information changes, then you have to be flexible enough—and humble enough—to be able to change how you think about things.” abcn.ws/32pBD6L

After receiving two doses of the vaccine, all 45 participants developed so-called neutralizing antibodies against the virus.

The CRISPR-Cas system, naturally found in many prokaryotes, is widely used for genome editing. CRISPR arrays in the bacterial genome, derived from the genome of invading viruses, are used to generate a CRISPR RNA that guides the Cas enzyme to destroy repeat viral invaders. Recently, an unexpectedly compact CRISPR-Cas system was identified in huge bacteriophages. Pausch et al. show that even though this system lacks commonly found accessory proteins, it is functional. In addition to a CRISPR array, the only component of the system is an enzyme called CasF, which uses the same active site to process transcripts of the CRISPR arrays into CRISPR RNA and to destroy foreign nucleic acids. This system, which is active in human and plant cells, provides a hypercompact addition to the genome-editing toolbox.

Science this issue p. 333

CRISPR-Cas systems are found widely in prokaryotes, where they provide adaptive immunity against virus infection and plasmid transformation. We describe a minimal functional CRISPR-Cas system, comprising a single ~70-kilodalton protein, CasΦ, and a CRISPR array, encoded exclusively in the genomes of huge bacteriophages. CasΦ uses a single active site for both CRISPR RNA (crRNA) processing and crRNA-guided DNA cutting to target foreign nucleic acids. This hypercompact system is active in vitro and in human and plant cells with expanded target recognition capabilities relative to other CRISPR-Cas proteins. Useful for genome editing and DNA detection but with a molecular weight half that of Cas9 and Cas12a genome-editing enzymes, CasΦ offers advantages for cellular delivery that expand the genome editing toolbox.